Echo Therapeutics Starts Clinical Study of Its Symphony(TM) Continuous Transdermal Glucose Monitoring System



    FRANKLIN, Mass., Jan. 2 /CNW/ -- Echo Therapeutics, Inc. (OTC Bulletin
Board: ECTE) announced today that it has started the second clinical study of
its current Symphony(TM) Continuous Transdermal Glucose Monitoring System
(CTGM System) at the Tufts-New England Medical Center (Tufts-NEMC).  The
Company expects to announce the results of the study in the first quarter of
2008. Echo's current generation Symphony CTGM System consists of the
FDA-cleared SonoPrep(R) skin permeation device that incorporates patented and
leading-edge permeation control technology, together with wireless
conductivity and proprietary transdermal sensor technologies.  In addition to
providing glucose monitoring benefits to diabetes patients, Symphony is
designed to help patients and healthcare teams in hospital critical care
settings to better control glucose levels with accurate, needle-free,
continuous glucose readings.
    "We have made significant progress in the development of our core
components of both current and next generation Symphony CTGM Systems. Our
permeation control technology is a competitively unique element of our
non-invasive, transdermal skin permeation approach for the Symphony system.
The primary goal of this study is to expand the strong data set we generated
with our current Symphony CTGM System in our prior study at Tufts-NEMC, while
also focusing on further advancements to our transdermal sensor technologies
we currently expect to bring to market in 2009," stated Patrick T. Mooney,
M.D., Echo's Chief Executive Officer. "We believe that non-invasive,
transdermal continuous glucose monitoring in the critical care setting is a
large and emerging market for Symphony.  In addition, we believe that Symphony
will offer diabetes patients in the home use market a convenient, needle-free
and cost-effective continuous glucose monitoring system to help avoid
complications related to poor glycemic control by providing better predictive
information regarding glucose trends. We are very excited about our progress,
and we look forward to important advancements related to Symphony in early
2008."
    Stanley A. Nasraway, M.D., Director of Surgical Intensive Care Units at
Tufts-NEMC and Principal Investigator of the study, noted the following about
the application of Symphony in the hospital setting, "We need to improve the
monitoring of blood glucose, from the current standard of once every 1-2
hours.  It is clear that critical care patients need tighter glycemic control
in order to minimize morbidity and mortality in the critical care setting.
Echo's ability to provide patients a continuous, needle-free blood glucometry
is very attractive.  When this happens, blood glucose measurements will become
the 5th Vital Sign, and tighter glycemic control, without serious
hypoglycemia, will be the standard of care for all seriously ill hospitalized
patients, worldwide."
    Echo's study at NEMC will enroll twenty-five (25) patients undergoing
cardiac bypass graft surgery and will evaluate the safety and efficacy of its
current generation Symphony CTGM System in a hospital setting by comparing
Symphony's wireless, needle-free, real-time blood glucose (BG) monitoring to
results of traditional BG monitoring in the intra-operative and post-operative
critical care settings.  A secondary goal will evaluate the reliability of
Symphony in adverse conditions, such as during cardioplegia, use of
vasopressors, transfused blood elements, diaphoresis, obesity, hypothermia and
significant peripheral edema.
    The skin permeation feature of Echo's current generation of Symphony CTGM
System involves SonoPrep, Echo's FDA-cleared device using ultrasound-mediated
skin poration technology.  Pursuant to a license agreement, Echo granted Bayer
an exclusive license to the current generation Symphony CTGM System in the
worldwide markets.  The parties subsequently agreed to an amendment to the
license agreement whereby Bayer agreed to a co-exclusive license with Echo to
the current generation Symphony CTGM System in the hospital intensive care
unit market.  Based on Echo's recent internal technical advances relating to
its next generation Symphony CTGM System, Echo will expand its offerings of
skin permeation devices beyond its SonoPrep System used in its current
generation Symphony CTGM System.  Currently, Echo and Bayer do not intend to
utilize ultrasound techniques for skin permeation in future transdermal
glucose monitoring devices for the home use market.  As such, Bayer was not
obligated to make a $2 million milestone payment to the Company on or before
December 31, 2007 under Echo's agreement with Bayer.  Bayer retains a
co-exclusive license to Echo's current generation Symphony CTGM System using
ultrasound skin permeation techniques in the worldwide markets, but no longer
has a right of first refusal for the marketing of Echo's CTGM System that
makes use of ultrasound skin permeation methods.  Bayer does not have
commercial rights to Echo's next generation Symphony CTGM System.
    Echo expects to announce its progress with respect to its next generation
Symphony CTGM System, including its advanced skin permeation strategy, in the
first-half of 2008.  Echo's discussions with prospective strategic partners
for development and marketing of its next generation Symphony CTGM System are
ongoing.
    
    About Echo Therapeutics
    
    Echo Therapeutics is a platform-enabled specialty therapeutics and
diagnostics company developing a broad pipeline of both advanced topical
reformulations of FDA-approved products using its proprietary AzoneTS(TM)
dermal penetration technology, and Symphony(TM), a next generation wireless,
needle-free, continuous transdermal glucose monitoring (CTGM) system for the
diabetes and hospital critical care markets.
    (C) 2008 Echo Therapeutics, Inc., SonoPrep is a registered trademark of
Echo Therapeutics, Inc.  All other company, product or service names mentioned
herein are the trademarks or registered trademarks of their respective owners.
    
    Safe Harbor Statement
    
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current expectations,
but are subject to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current expectations
include, but are not limited to, risks related to regulatory approvals and the
results of Echo's ongoing studies regarding the efficacy of Echo's current and
next generation Symphony(TM) CTGM System, which include delays in enrolling
patients and volunteers into clinical studies, lower than anticipated
retention rates of patients and volunteers in clinical studies, the need to
repeat clinical studies as a result of inconclusive or negative results or
poorly executed testing, insufficient supply or deficient quality of product
candidate materials or other materials necessary to conduct clinical studies,
serious and unexpected adverse device effects experienced by participants in
clinical studies, or the suspension of clinical studies, any of which could
delay or prevent commercialization of Echo's Symphony(TM) CTGM System product
candidates; the failure of future development and preliminary marketing
efforts related to Echo's next generation Symphony(TM) CTGM System; risks and
uncertainties relating to Echo's ability to develop, market and sell
diagnostic products based on its skin permeation platform technologies,; the
availability of substantial additional equity capital to support robust
research, development and product commercialization activities; and the
success of research, development, and regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to both Echo's current and next generation Symphony(TM) Continuous
Transdermal Glucose Monitoring System.
    These and other factors are identified and described in more detail in
Echo's filings with the Securities and Exchange Commission, including, without
limitation, Echo's respective annual reports on Form 10-KSB for the year ended
December 31, 2006, Echo's most recent quarterly reports on Form 10-QSB, and
Echo's current reports on Form 8-K.  The foregoing list of factors is not
exhaustive.  Echo Therapeutics, Inc. undertakes no obligation to publicly
update or revise any forward-looking statements.

    
     For More Information:
     Patrick T. Mooney, MD                         Laura Perry
     Chief Executive Officer                       Stern Investor Relations
     (856) 429-8778                                (212) 362-1200
    




For further information:

For further information: Patrick T. Mooney, MD, Chief Executive Officer
of  Echo Therapeutics, Inc., +1-856-429-8778; or Laura Perry of Stern Investor
 Relations, +1-212-362-1200, for Echo Therapeutics, Inc.

Organization Profile

ECHO THERAPEUTICS, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890